Wednesday 28 December 2016

Global Medical Laser Systems Market Share, By Key Players 2018

The global market for medical laser systems features a large number of domestic and international vendors and is highly competitive, observes a recent report by Transparency Market Research (TMR). Low options of product differentiation and availability of cheaper products manufactured by local companies make price rivalry increasingly intense in the market. The effect of these challenges, however, is expected to be subsided due to the presence of vast growth opportunities, especially across developing economies. Some of the key vendors in the market are Lumenis Ltd., PhotoMedex, Inc., Spectranetics Corporation, Novadaq, Syneron-Candela, AngioDynamics Corporation, BioLase, Inc., and Iridex Corporation.

Transparency Market Research states that the global medical laser systems market will exhibit a healthy double-digit rate of growth over the forecast period and rise to US$2,031.0 mn by 2018.


Diode Lasers, North America to Continue to Hold Dominant Positions

Of the key varieties of medical laser systems examined in the report, the segment of diode lasers holds the dominant market share and is expected to retain its dominant stance in the global market over the forecast period as well. This can be chiefly attributed to the use of these lasers in a wide array of medical applications such as photodynamic therapy and numerous aesthetic treatments. However, the segment of solid state lasers is expected to exhibit the most significant rate of growth over the forecast period. Factors such as availability of several variants of these lasers, each of which find specific applications in medical treatments such as tattoo removal, periodontology, and skin treatment will be the key growth drivers.

In terms of geography, the global medical laser systems market is dominated by North America, chiefly owing to the increased prevalence of chronic diseases such as diabetes and obesity in the region. However, the Asia-Pacific medical laser systems market will exhibit the most promising growth over the forecast period and will benefit from the presence of high growth opportunities in terms of unmet medical requirements in emerging economies such as India and China.

Significant Rise in Age-Related Ocular Disorders to Augment Market’s Growth Prospects

With the significant and rapid rise in the geriatric population of the globe, the number of patients suffering from age-related ophthalmic disorders such as macular degeneration, presbyopia, diabetic retinopathy, and cataract is also rising globally. Cataract is one of the most common of these diseases and the corrective surgery commonly involves medical lasers. Recent statistics denote that the number of cataract surgeries performed in 2020 will be nearly 4 mn, representing a rise of more than 1 mn of that in 2010. Along with this factor, the prevalence of other eye disorders and the necessary corrective surgeries involving lasers will act as high-impact drivers for the global medical laser systems market over the report’s forecast period.

Strict and Globally Variable Regulatory Standards to Hamper Market Growth

One of the key challenges of using lasers in the medical field is the need for compliance with several safety-related procedures and norms. Laser safety norms also differ with countries and laser manufacturers require several certifications and approvals before commercializing their products. This need to adhere to a vast array of different rules and regulations across several countries, owing to factors such as variation in stringency level of approval bodies and presence of several approval bodies, dampens the spirit of companies, especially small-scale ones, and may result in lesser number of companies wanting to foray into the field.

Browse Full Research Report on Medical Laser Systems Market:
http://www.transparencymarketresearch.com/medical-laser-systems-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Analysis for Newborn Screening Market by Key Players 2023

Transparency Market Research has collected a detailed set of factors that are expected to influence the global newborn screening market. This data is presented in a research report titled “Newborn Screening Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 – 2023.”

When it comes to physical growth and the maintenance of well-being, there is a list of disorders that a newborn could be affected by. These disorders, either inherited or metabolic, make it important for doctors to know exactly what might happen during the crucial initial phase of a newborn’s growth period.

Newborn screening is therefore one of the most important practices in modern medicine. It involves testing various fluids and tissues of a child immediately after birth. Blood samples are taken, from which doctors can test the baby’s enzyme activity and metabolites after they are gathered using a specialized filter.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4581

Using the various tests devised under newborn screening, doctors can ascertain whether or not a child could suffer from any form of impairment to his or her normal growth. If the newborn is tested positive, the medical professionals can give the parents specific advice on taking care of the baby, and also provide drug and therapeutic assistance depending on the problem. If a child is tested positive, then follow-up tests are also scheduled under the guidance of a geneticist and a pediatrician.
The global newborn screening market also includes testing for congenital heart defects and hearing loss. They are usually conducted through state or even national governing bodies that work to screen all hospital births within their region. There is currently no standardized list or pattern of newborn screening, which is why the types of screenings will differ greatly between different regions.

The global newborn screening market is advancing due to the influx of new players in the past few years. It is, however, continually impeded by factors such as the lack of infrastructure in several regions, the overall lack of awareness, and the lack of trained professionals.

In 2013, the National Institute of Health initiated a program for newborn screening, which involved genomic sequencing. The program helped the global newborn screening market make giant leaps in terms of researching the difficulties encountered during newborn genomic sequencing and ways to mitigate these complications.

Geographically, the global newborn screening market has consistently been dominated by North America, followed by Europe, owing to a highly developed healthcare infrastructure, higher spending power, and improved insurance coverage. At the same time, Asia Pacific is exhibiting a rapid growth rate due to a fast-evolving medical industry and the increasing rate of awareness. This region additionally benefits from the growth of medical tourism along with government initiatives against newborn diseases.

The key players in the global newborn screening market are ZenTech S.A., PerkinElmer Inc., Natus Medical Inc., Masimo Corporation, GE Life Sciences, BioTek Instruments, Inc., and Bio-Rad Laboratories.

Browse Full Research Report on Newborn Screening Market:
http://www.transparencymarketresearch.com/newborn-screening-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Atherectomy and Thromboctomy Devices Market By Technology 2023

Atherectomy is one of the important peripheral arterial disease treatment, in which, atherosclerosis from large blood vessels are removed by using minimally invasive surgical approach. In addition, this technique is used for the treatment of coronary arterial diseases. Thromboctomy, also known as pulmonary thromboctomy, is an emergency medical treatment, by which thrombus (blood clot) is removed from arteries and veins. Thromboctomy can be performed by two technologies, by using surgery or by percutaneous techniques. However, surgical thromboctomy technique is used rarely, due to less efficient results and high cost.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=4584

Atherectomy technique is a popular substitute for stents and angioplasty treatment. In case of latter, the deposited plaque is pushed inside blood vessel, however, in former, the plaque is removed by using surgical or mechanical technique. This technique has certain advantages over angioplasty and stents, such as, increased wound healing rate, reduction in claudication, reduction in threat of cardiac and other medical complications, less invasive nature, faster patient recovery, high repeatability, ease-of-performance and many others. The device is inserted in the body by making small incision to certain locations of body, such as, common femoral artery, political artery, bronchial artery and others.

The market of Atherectomy devices is segmented on the basis of type and mechanism of device functions, such as, orbital, laser, rotational and directional devices. However, preference of device is based on factors such as, nature and size of plaque, anatomical place to be treated, and surgeon’s expertise. The market for thromboctomy is also segmented on the basis of device type, such as, rotational, ultrasound enhanced and rheolytic thromboctomy devices. In addition, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, the North American region is the most prominent market, owing to increasing technological intervention in cardiac disease management. However, Asia-Pacific and some countries in RoW region are expected to show very lucrative growth in the upcoming period, owing to enhanced awareness and growth in prevalence of cardiac patients and technologies.

The market for atherectomy and thromboctomy devices is expected to grow in the upcoming future at a lucrative rate, due to various market drivers, such as rapid increase in the cardiac diseases, changed life-style, increasing preference towards less invasive cardiac disease management practices, less risks involved in the procedure, decreased use of surgical practices for cardiac diseases treatment and technological growth in the development of advanced devices. Rising prevalence of cardiac disorders is one of the most important market driver. According to the U.S. Center for Disease Control and Prevention (CDC), around 0.6 million of Americans die every year due to cardiac diseases, and around 720,000 Americans have a heart attack every year. Further, changed life-style is another contributor for the market growth. Due to consumption of junk food, addiction and lack of exercise, the prevalence of cardiac diseases have been increased and it contributes the market growth of Atherectomy and thromboctomy devices. On the contrary, major restraints that impose hurdles in the market growth include high cost, limited awareness in certain region of the world. Key opportunities include development of cost-effective therapy and strong focus on APAC region (since, India and China possess the largest number of cardiac patients).

Some of the major players operating in the market include Bayer AG, Cardiovascular Systems, Inc., St. Jude Medical Inc., Boston Scientific Corporation, C.R. Bard, inc., Teleflex Medical Inc., and Covidien, Inc. among others.

Browse Full Research Report on Atherectomy and Thromboctomy Devices Market:
http://www.transparencymarketresearch.com/atherectomy-thromboctomy-devices-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Friday 23 December 2016

North America Porcine Vaccine Market to US$926.2 Million by 2024

North America Porcine Vaccine Market: Snapshot

For several decades, vaccination has remained one of the most important interventions for disease prevention among humans and animals. In veterinary medicine, vaccination has proven to be a boon for animal health. Diseases such as diarrhoea, swine influenza, porcine reproductive and respiratory virus (PRRSV), porcine circovirus associated disease (PCVAD), have been greatly reduced from spreading endemic in several cases. Some diseases such as foot and mouth disease and cholera high fever in swines have been significantly eliminated in North America with the help of vaccination. 

The market for porcine vaccine in the region is expected to exhibit healthy growth in the next few years as well. The rising demand for meat and gelatin and concerns regarding the rising pace of occurrence of zoonotic diseases will be the key factors driving the market in the near future. Transparency Market Research estimates that the North America porcine vaccine market will expand at a 5.3% CAGR from 2016 to 2024. As a result, the market, which valued at US$540.9 mn in 2015, will rise to US$926.2 mn by 2024. 


Inactivated Vaccines to Remain Most Preferred

In terms of the technology used to develop vaccines, the North America porcine vaccines market has been segmented into inactivated vaccines, live attenuated vaccines, recombinant vaccines, toxoid vaccines, DNA vaccines, and conjugate vaccines. Of these, the segment of inactivated vaccines dominated the market in 2015 and is expected to account for a 53.3% of the North America veterinary vaccine market in 2016. The segment is also expected to exhibit the most promising growth in the near future, expanding at a 6.7% CAGR over the period between 2016 and 2024. 

The segment of live attenuated vaccines will exhibit a strong 5.9% CAGR over the said period. Rise in the number of swine farms, rising prevalence of zoonotic disease, and increase in investments by key players are likely to drive the live attenuated vaccine segment. The DNA vaccine segment is projected to emerge as a high-growth segment owing to rise in demand and increase in R&D investments. DNA vaccines have shown excellent results in granting strong immunity against homologous infections and have a good score in terms of approval from regulatory bodies in the region. As a result, the demand for these vaccines is expected to rise at a healthy pace in the region over the forecast period.

U.S. Market to Continue to Account for Dominant Chunk in Sales

The North America porcine vaccine market has been examined for two countries in the region: the U.S. and Canada. The U.S. market for porcine vaccines accounted for a larger 63% share in the North America market in 2015. The U.S. porcine vaccine market is expected to exhibit the most lucrative 6.6% CAGR over the period between 2016 and 2024. Factors such as well-established infrastructure in immunological research, high concentration of key players, highly organized farming structure, increased demand for animal protein, and rising expenditure on animal health by farm owners are attributed to the dominant share of the country in the North America market. 

The market in Canada is also anticipated to expand at a healthy, but comparatively lower CAGR of 5.8% from 2016 to 2024. Factors such as the rising prevalence of PRRS virus and PCV2 among herds and rising focus of key players on R&D activities for the development of effective vaccines will contribute to the growth prospects of the Canada porcine vaccines market in the near future. Moreover, export and import permits among contract manufacturers or distributer firms and low estimated cost of products are also expected to make the porcine vaccine market more popular in Canada. 

Some of the key players in the market are Bayer AG., Bimeda Animal Health, Boehringer Ingelheim GmbH, Ceva Santé Animale, Merck & Co., Inc., Merial (Sanofi), Vetoquinol, Zoetis, Inc., Elanco (Eli Lilly and Company). 


About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Monday 19 December 2016

Global Medical Education for Neurology Training Market Revenue and Forecast 2024

Medical Education Market: Snapshot

The medical education market is set to boom in the near future thanks to major advances made in the field of medical science, the surging incidence of chronic illnesses, increased incidences of various types of cancer, technological innovations, and the frequent introduction of new courses. The online learning space has grown manifold, especially in developed countries, owing to the growth of the online education market, the increased preference of updated and diverse courses, the development of new start-ups, and higher internet penetration.

Transparency Market Research predicts that the global medical education market is poised to expand at a 4.3% CAGR during the forecast period, rising from a value of US$25.9 bn in 2015 to US$38.4 bn by 2024.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=517

Rising Incidence of Cardiovascular Diseases Spurs Cardiothoracic Education and Training

Medical education includes training in a number of disciplines, including cardiothoracic, neurology, orthopedic, oral and maxillofacial, pediatric, radiology, and laboratory. The cardiothoracic training segment led the medical education market in 2015 by revenue, driven by the rising incidence of cardiovascular diseases, especially coronary blockages. The effectiveness of cardiothoracic training in treating these diseases and curbing side effects such as thrombosis and restenosis associated with a percutaneous coronary intervention (PCI) has also fueled the growth of this segment. Other factors that drive the cardiothoracic training segment are the effective management of heart diseases, rising awareness among patients, and increased medical needs such as surgeries and diagnosis. The radiology training segment is likely to expand at the highest CAGR during the forecast period

Technological Innovations and Upgrades Driving Medical Education in North America and Europe

Geographically, the medical education market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.

North America was the leading market for medical education in 2015, followed by Europe. Being a well-established region in terms of medical education and healthcare, North America is likely to retain its dominant share throughout the forecast period. The medical education market offers immense growth potential in this region due to timely technological upgrades, increased awareness among patients, and the continuous evolution of information technology.

The growth of the medical education market in Europe is attributed to technological innovations, the consistent introduction of new courses, and increasing healthcare expenditure. In addition, the increased implementation of picture archiving and communication systems (PACS) and stable healthcare education policies widens the scope for growth and acceptance of medical education in this region.

Asia Pacific has been witnessing increased adoption of online training for medical education. Rapidly evolving healthcare infrastructure, the rising number of researchers in the medical field, several initiatives taken by government organizations to provide scholarships and economic relief to medical students, and the presence of a large pool of patients suffering from various types of cancers and cardiovascular diseases in countries such as India and China are some of the key factors driving the medical education market in Asia Pacific.

Apollo Hospitals, TACT Academy for Clinical Training, Zimmer Biomet Holdings, Inc. (Zimmer Institute), Olympus Corporation, Gundersen Health System, GE Healthcare, and Medical Training College are some of the leading players in the global medical education market. 

Browse Full Research Report on Medical Education Market:
http://www.transparencymarketresearch.com/medical-education-market.html
About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Global Kaposi Sarcoma Market, By Type of Treatment Snapshot in 2024

The global market for Kaposi sarcoma is projected to expand at a modest 2.2% CAGR from 2016 to 2024, with the opportunity in the market rising from US$118.5 mn in 2015 to be worth US$143.2 mn by the end of the forecast period. Hospitals formed the leading distribution channel in 2015, generating over US$40 mn revenue that year. The segment is also slated emerge as the fastest growing segment in the KS market, expanding at a 2.6% CAGR from 2016 to 2024.


Kaposi sarcoma is a soft tissue sarcoma that develops in connective tissues, blood vessels, fibrous tissues, and muscles. It is a malignant, multi-centric, neoplastic vascular proliferation, characterized by the development of bluish-red cutaneous nodules on the feet. According to the U.S. Center for Disease Control and Prevention (CDC), Kaposi sarcoma is considered an acquired immune deficiency syndrome (AIDS) defining disease. This report analyzes the current and future prospects of the Kaposi sarcoma market based on type of treatment, distribution channel, and geography.

The report is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of major Kaposi sarcoma therapies in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, and various international and national databases. The report provides estimated market size in terms of US$ Mn for each treatment method, distribution channel, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each treatment method was calculated by considering number of patients, average cost of the drugs, trends in the industry, distribution channel trends, and adoption rate of therapy across all the geographies. The revenues generated from services, including surgery and radiation therapy were calculated based on the costs and average number of procedures.

The market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on type of treatment, distribution channel, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints, and opportunities that influence the Kaposi sarcoma market in the current and future scenario. The report provides the list of drugs in various stages of clinical trials, which are expected to shape the future course of the market, through pipeline analysis. The report also provides value chain analysis of the market that describes the sequence of activities from drug manufacturing to the final destination, which is the end user.

Market share analysis is provided to highlight percentage share of the major players operating in the market. All these factors will help market players to decide business strategies and plans to strengthen their position in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. Market forecast for major countries in these regions have also been provided for the forecast period.

In addition, this report includes a list of recommendations to aid new entrants and established players in taking strategic initiatives to strengthen their presence in the market. The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the Kaposi sarcoma market report are Bristol - Myers Squibb, Eli Lilly and Co., Hoffman-La Roche, Inc., GlaxoSmithKline plc, Johnson & Johnson, Pfizer, Inc., and Schering Plough Corporation (Merck & Co., Inc.)

Browse Full Research Report on Kaposi Sarcoma Market:
http://www.transparencymarketresearch.com/kaposis-sarcoma-market.html
About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Friday 16 December 2016

With Increased Fragmentation, U.S. Market for Bacterial Conjunctivitis Drugs to Face Major Setback in Profits

​The U.S. market for bacterial conjunctivitis drugs has been declining sharply over the last few years. Analysts project the trend to continue in the coming years. In 2013, the market’s opportunity was valued at US$473.3 mn, which is likely to reduce to US$439.8 mn by 2024. In the coming years, the market will have to experience a patent cliff as the top U.S. brands of bacterial conjunctivitis drugs, such as AzaSite, Zymaxid, Moxeza, and Vigamox, are set to lose their marketing exclusivity very soon.


The growing genericization of antibacterial drugs has impacted the demand for branded drugs significantly. The generic versions of patented formulations, with almost same efficiency as the latter, are easily available at much lower rates in the market. This has increased the sales volume, albeit at the cost of revenues. Many branded ophthalmic drug manufacturers have incurred huge losses due to the generic cannibalization in this market.

Rising Prevalence of MDROs Creates Serious Challenge for Market’s Growth

Apart from this, the rising prevalence of multi-drug resistant organisms (MDROs), triggered by wide usage of antibiotics, incorrect drug dosage, and inappropriate medications, has created serious challenges for the treatment of infections such as bacterial conjunctivitis. Researchers across the world are working on discovering efficient drugs for these MDROs. However, the non-availability of effective medications in near future is likely to hamper the market’s growth over the coming years.

Although the market is facing a number of restraints at present, it may experience a little relief in future if the product development partnerships (PDPs) models for business are implemented by participants. As various research and development procedures incur a high amount, exerting substantial pressure on pharma companies, strategic alliances with small biotech research organizations will prove to be beneficial for both the parties.

Market Encroachment by Generic Variations to Limit Demand for Topical Fluoroquinolones

Fluoroquinolones, macrolides, and aminoglycosides are the major classes of drugs used for the treatment of bacterial conjunctivitis. The demand for topical fluoroquinolones is the highest among all classes of bacterial conjunctivitis drugs in the U.S. However, the segment is projected to be hindered severely in the coming years, owing to the forthcoming patent expirations of bestselling drugs of this class, such as Vigamox, Moxeza, and Zymaxid by the end of 2016.

The market’s opportunity will also be hurt significantly over the next few years due to the encroachment by generic variations of these drugs and decline from US$361.9 mn in 2013 to US$286.4 mn by 2024.

Imminent Patent Expiries to Hurt Leading Players Severely

Valeant Pharmaceuticals Int. Inc., Santen Pharmaceutical Co. Ltd., Pfizer Inc., Perrigo Com. Plc., Novartis AG, Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Akorn Inc., and Actavis Plc. are leading the market for bacterial conjunctivitis drugs in the U.S. The imminent patent expiries is likely to hurt the business of these players significantly in the near future. However, the rising prevalence of bacterial infection in eyes and the increasing susceptibility to infection among individuals of various age groups may provide rewarding opportunities to participants over the next few years.

Players are recommended to focus on developing herbal medicines for the treatment of bacterial conjunctivitis, as the consumer preference is shifting from pharmacological medicines to herbal treatment regimens.

Browse Full Research Report on Bacterial Conjunctivitis Drugs Market:
http://www.transparencymarketresearch.com/us-bacterial-conjunctivitis-drugs-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Single-use Bioprocessing Systems Market Asia Pacific and North America to Lead Market Growth during Forecast Period

Transparency Market Research has published a new market report titled, “Single-use Bioprocessing Systems Market: (By Product – Bioreactors & Fermenters, Mixers, Bags, Bioprocess Containers, Filtration Devices, Tubing, Sampling Systems, Connectors & Clamps, Probes & Sensors; By End-user – Pharmaceutical, Biotechnology, CRO & CMO, and Academic & Research Institutes; By Application – Monoclonal Antibody Production, Vaccine Production, Plant Cell Cultivation, Patient Specific Cell Therapies, and Others) – Global & North America Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2016–2024.” According to the report, the global single-use bioprocessing systems market was valued at US$ 2,356.8 Mn in 2015 and is projected to expand at a CAGR of 11.1% from 2016 to 2024 to reach US$ 5,914.6 Mn in 2024. This report offers a thorough understanding of the global single-use bioprocessing systems market, its key trends, drivers, restraints, opportunities and threats.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3753

Single-use bioprocessing systems are disposable equipment and consumables used in research and development as well as commercial production of biological drugs and metabolites. The adoption of single-use bioprocessing systems has seen a paradigm shift in recent years compared to its market over a decade ago. This implies that until recently, bio-production facilities relied on the use of fixed and non-portable stainless steel equipment such as large bioreactors and tanks to culture large volumes of fluid and hold buffers. However, currently, there is a growing acceptance of single-use technologies across the manufacturing process. Technological developments have enabled continuous single-use manufacturing a possibility, driven by the fact that several features of single-use bioprocessing products are continually evolving and improving.

In terms of market share, North America and Europe dominated the single-use bioprocessing systems market in 2015 and are projected to retain their dominant position during the forecast period from 2016 to 2024. This leadership position can be attributed to the fact that CRO’s & CMO’s, and niche biotechnology and multiproduct biopharmaceutical organizations in this region have been early adopters of single-use technologies compared to their counterparts in the emerging markets. The leadership in terms of revenue share is likely to sustain due to cutting edge research and development in biologics being centered in these regions globally. It has been postulated that the purchase of single-use systems would be higher in regions which lay greater emphasis on innovation and in regions where developments in bioscience are clustered. Moreover, many leading vendors are headquartered in North America and Europe, where they have higher share of product sales. Of the top 10 best-selling biological drugs of 2014, five were monoclonal antibodies, four were recombinant proteins, and one was a vaccine. This trend directly percolates to the application segment of the single-use bioprocessing systems market. For instance, in 2015, the highest revenue gaining application segment in both Europe as well as North America was monoclonal antibodies production followed by ‘others’ segment which includes recombinant proteins and enzymes. Together, these segments accounted for over 67% share in North America and over 71% share in Europe of the single-use bioprocessing systems market in 2015.

The pharmerging region of Asia Pacific has a booming biotechnology and biopharmaceutical industry. Moreover, many pharmaceutical organizations are providing contract research services to CRO’s & CMO’s in India and China. Furthermore, many countries in Asia Pacific have a higher cancer and infectious disease burden than the developed world, which implies that the disease burdened population is at a higher need for new cancer therapies and vaccines. Single-use bioprocessing systems will aid to address the unmet needs for a population which requires medicines that are cheaper and take reduced time to market. Driven by the booming biopharmaceutical and contract manufacturing sector and coupled with greater therapeutic needs of the population, the single-use bioprocessing systems market in Asia Pacific is set to expand at a rate higher than the global average during the forecast period from 2016 to 2024. This is attributable to the market seeing an influx of single-use vendors opening offices in countries in Asia Pacific for enhancing business in this region. For instance, in January 2015, Finesse Solutions opened a subsidiary office in Shanghai to serve the active Chinese market for single-use bioprocessing systems, as well as serve major areas of biotech expansion such as Seoul, Tokyo, and Singapore.

Collectively, Latin America and Middle East & Africa contributed to over 23% of the global market share for single-use bioprocessing systems in 2015. The market in these regions has not yet picked up pace as Europe, North America, and Asia Pacific; however, the proximity to North America coupled with increase in contract manufacturing activities is expected to drive the rise in adoption of single-use bioprocessing systems in these markets. A gradually rising biotechnology sector in the UAE as well as South Africa would propel the market for single-use technologies in these countries. However, a skills gap exists in these countries due to which the adoption of single-use technologies may face a restraint during the forecast period. Overall, the MEA and LATAM markets are likely to grow at a rate less than the global average due to late adoption of single-use systems. Despite this, the benefit of cost savings and rapid research would augment market growth in these regions during the period from 2016 to 2024.

Thermo Fisher Scientific, Merck KGaA (Merck Millipore), Danaher Corporation (Pall Corporation), Sartorius AG, Eppendorf AG, GE Healthcare, PBS Biotech, Inc., Meissner Filtration Products, Inc., Finesse Solutions, Sentinel Process Solutions, and Saint-Gobain are the key players operating in this market.

Browse Full Research Report on Single-use Bioprocessing Systems Market:
http://www.transparencymarketresearch.com/single-use-bio-processing-systems-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Wednesday 14 December 2016

Radiofrequency Ablation Devices for Pain Management Market: Consumer Preference for Minimally Invasive Pain Management Options to Boost Growth Opportunities

The radiofrequency ablation devices for pain management market features a markedly high level of consolidation, with the top three vendors,  St. Jude Medical, Inc., Halyard Health, Inc., and Boston Scientific Corporation, accounting for a share of over 88% in 2015, observes Transparency Market Research. “These companies have strengthened their hold on the market owing to diversified product portfolios, extensive geographical presence, and strategic acquisitions over the past few years,” states a TMR analyst. Increased focus on emerging economies and increase in product launches are some of the most popular strategies adopted by top players.

Transparency Market Research states that the global radiofrequency ablation devices for pain management market, which valued at US$372.7 mn in 2015, is expected to rise to US$1,114.5 mn in 2024. This translates to a potential 13.0% CAGR over the period between 2016 and 2024.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=985

In terms of product varieties, the segment of disposable RF products dominated, accounting for a 40% of the overall market in 2015. The segment of RF generators is expected to exhibit expansion at the most promising pace over the forecast period. From a geographic perspective, the market in North America dominated in 2015, accounting for over 40% of the global market in 2015. However, the global market is expected to witness most lucrative growth opportunities in emerging economies across regions such as Asia Pacific and Latin America over the forecast period.

Rising Prevalence of Chronic Pain to Have Sizeable Positive Impact on Market Growth

The rising prevalence of chronic pain conditions and the rising geriatric population of the world are among the key factors leading to the rising global demand for pain management therapies such as the ones that use radiofrequency ablation devices. The global market for these devices for pain management is also highly influenced by the rising demand for minimally invasive procedures across the globe.

Benefits such as lesser post-surgery complications, low chances of side effects, and shorter span of recovery work in favor of minimally invasive surgeries and related devices. Radiofrequency ablation devices for pain management are also gaining increased focus owing to the higher known side effects and lower efficiency of alternate pain relief procedures and therapeutics options such as acupressure, acupuncture, and opioids. The easy availability, cost-effectiveness, and easy access to highly effective radiofrequency ablation devices for pain management have also propelled the market for these devices of late.

Regulatory Hurdles Delaying Approval of New Devices to Hamper Market Growth

The need to comply with stringent laws and regulations set by regulatory authorities that are closely associated with product approvals, clinical trials, design, development, and commercialization hamper the overall development of the market to a sizable extent. Ablation devices come under class III medical device category in Europe and the U.S. Owing to this, the efficacy and safety of devices such as catheters and generators are paramount to gain approval. Strict regulations do not only delay approval, launch, and marketing of these products but also lead to increased prices.

Decisions of regulatory authorities and cost containment measures undertaken by government authorities also have a negative impact on the reimbursement scenario and restrain the market for radiofrequency ablation devices for pain management. Along with these factors, the low costs of several pain management therapeutic options such as anticonvulsants, antidepressants, and NSAIDs also significantly impact and restrain the overall development of the global radiofrequency ablation devices for pain management market.

This review of the market is based on a market research report recently published by Transparency Market, titled “Radiofrequency Ablation Devices for Pain Management Market (Product - RF Generators, Reusable Products, and Disposable Products; End-user - Specialty Clinics, Ambulatory Surgical Centers, and Hospitals) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Browse Full Research Report on Radiofrequency Ablation Devices for Pain Management Market: 
http://www.transparencymarketresearch.com/radiofrequency-ablation-devices.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Hepatitis E Diagnostic Tests Market: Fueled by Lack of Potable Water, Hepatitis E Hyperendemicity to Drive Growth

Global Hepatitis E Diagnostic Tests Market: Snapshot

The hyper-endemic prevalence of hepatitis E in various economies across the world, specifically in Asia Pacific, is likely to boost the need for hepatitis E diagnostic tests, globally in the coming years. The global hepatitis E diagnostic tests market, which was valued at US$43.7 mn in 2015, is projected to expand at a CAGR of 3.80% between 2016 and 2024and rise to an opportunity worth US$60.4 mn by 2024.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16859

Demand for ELISA HEV IgM Test Kits to Remain Strong

ELISA HEV IgM test kits, ELISA HEV IgG test kits, and RT-PCR test kits are the main types of test kits available in the global hepatitis E diagnostic test market. Since ELISA HEV IgM test kits are utilized extensively in the primary tests for the diagnosis of hepatitis E infections, these kits have been registering a higher demand than other test kits. Supported by the growing seroprevalence of hepatitis E across the world, researchers expect the demand for ELISA HEV IgM test kits to continue to rise remarkably over the forecast period.

The RT-PCR test kits segment is likely to follow the ELISA HEV IgM test kits segment closely in the coming years. As RT-PCR test is considered as the direct test for the diagnosis of acute infections of hepatitis E, the demand for RT-PCR test kits is also expected to increase substantially in near future. On the flip side, the ELISA HEV IgG test kits segment is projected to report a modest progression over the years to come.

Asia Pacific to Maintain Dominance in Global Hepatitis E Diagnostic Tests Market

On the basis of geography, the global market for hepatitis E diagnostic tests is segmented into Europe, Asia Pacific, Latin America, North America, and the Middle East and Africa. In 2015, Asia Pacific led the worldwide market with a share of more than 42% and is projected to remain dominant over the forecast period. A number of Asian countries, such as India, Nepal, Pakistan, Bangladesh, Bhutan, Vietnam, Kazakhstan, Thailand, and Burma, suffer from hyperendemicity of hepatitis E, which leads to an increased need for hepatitis E diagnostic tests, supporting the growth of the Asia Pacific market.

Apart from this, the Middle East and Africa will also witness a prominent rise in the market for the hepatitis E diagnostic tests in the coming years on account of the growing prevalence of hepatitis E in several economies, such as Uganda, Kenya, Morocco, and Nigeria due to poor sanitation facilities and lack of safe drinking water. On the other hand, the markets in North America and Europe will not report any noteworthy growth in the near future due to the insignificant prevalence of hepatitis E.

Some of the leading companies in the global market for hepatitis E diagnostic tests are Primerdesign Ltd., MP Biomedicals LLC, Mikrogen GmBH, Fortress Diagnostics Ltd., Fast-track diagnostics Ltd., F. Hoffmann-La Roche Ltd., Dia.Pro - Diagnostic Bioprobes s.r.l, Biokit S.A., Beijing Wantai Biological Pharmacy, and Altana Diagnostics GmbH.

Browse Full Research Report on Global Hepatitis E Diagnostic Tests Market: 
http://www.transparencymarketresearch.com/hepatitis-e-diagnostic-tests-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Tuesday 13 December 2016

Asia Pacific Lateral Flow Diagnostic Tests Market at a CAGR of 5.7% from 2015 to 2023

On account of a handful of large regional players, the Asia Pacific lateral flow diagnostic tests market is somewhat consolidated, finds a report by Transparency Market Research (TMR). It is characterized by stiff competition among the leading market players, who are present across major types of applications. Some of the well-entrenched players in the Asia Pacific lateral flow diagnostic tests market are Alere, Inc., Beckman Coulter, Inc., Beckman Coulter and Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, and Bio-Rad Laboratories. Among them, Beckman Coulter, Inc., for example, presently operates in over four segments of the APAC lateral flow diagnostic tests market, making it one of the dominant players in the market.

Going forward, the TMR report predicts that continued innovation resulting in more sophisticated lateral flow diagnostic test procedures would further heat up competition among the companies in the market. The APAC lateral flow diagnostic tests market was worth US$2.3 bn in 2015. Expanding at a steady CAGR of 5.7%, it is slated to reach a value of US$3.586 in 2023.

Download Exclusive Global Strategic Business Report:
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7739

Japan to offer Lucrative Options for Investments and Sales to Global Market

The APAC market for lateral flow diagnostic tests can be divided on the basis of application into seven main parts, namely malaria, hepatitis, pregnancy, syphilis, HIV, influenza, and others. Among them, the pregnancy application segment led the APAC market for lateral flow diagnostic tests in 2014 due with a dominant share of US$0.6 bn in 2015 in 2015. This was mainly on account of the substantial demand for diagnostic kits to test fertility from females in the region. In terms of growth rate, however, the hepatitis application segment is forecasted to outpace all other segments as hepatitis B continues to affect a substantial proportion of the population. A World Health Organization (WHO) report states that between 5-10% of the adult’s population is affected by hepatitis B in East Asia.

The report also segments the APAC lateral flow diagnostics test market on the basis of regions. It finds Japan, which is the second significant individual healthcare market, to be a key country in the Asia Pacific region. This growth will be fueled by swift pace of infrastructural development, enhanced access to medical care, and rising thrust on research. The market is anticipated to rise at a CAGR of 4.5% from 2015 to 2023. Efforts to develop cost-effective diagnostic kits for Ebola by researchers at Nagasaki University are expected to help this country retain its lead in the coming years as well. Densely populated China and India, investing heavily in the healthcare sector will also up demand for lateral flow diagnostic tests.

Growing Instances of Chronic Maladies Propels Market

The healthcare spend in Asia Pacific has seen an upswing due to rising instances of maladies such as cardiovascular disorders, diabetes, cancer and infectious diseases. This has been pegged as an important driver of growth in the APAC market for lateral flow diagnostic tests. Another important factor boosting the market is growing demand for point-of-care diagnosis, which delivers faster results thereby lowering treatment cost and time. It also helps in thwarting complications resulting from delay.

A major deterrent to the market is the frequent inaccurate results. Explains the analyst of the report, “Lateral flow diagnostic tests are designed for tentative diagnosis at home or point-of-care setting. Due to low sensitivity, lateral flow diagnostic tests often deliver false results. Further, incorrect sampling during home testing may also contribute to error in disease testing. This might deviate treatment from the actual diagnosis and lead to further compilations. Although technological advances might overcome this drawback in future, lateral flow tests are seldom used for routine diagnosis due to this demerit.”

This review is based on the findings of a TMR report titled “Lateral Flow Diagnostic Tests Market - APAC Industry Analysis, Size, Share, Growth Trends and Forecast 2015–2023.”

Browse Full Research Report with TOC on Lateral Flow Diagnostic Tests Market:
http://www.transparencymarketresearch.com/apac-lateral-flow-diagnostic-tests-market.html

Hospital Acquired Infection Treatment Market Value Share Analysis, by Distribution Channel in 2024

The global hospital acquired infection treatment market in 2015 was dominated by a handful of players, including Abbott, Pfizer, Inc., Merck & Co., Inc., and Bayer AG. The market is currently in a state of battle with the growing count of generics available in the world, owing to an incoming wave of patent expirations. This could create a problem for players trying to maintain favorable profit margins.

According to a research report released by Transparency Market Research, the highly fragmented global hospital acquired infection treatment market holds a medium level of competition for players of all sizes. Key players are locked in rivalry for the development of treatments for alternative molecule therapies and multi-drug resistant pathogens. At the same time, the threat of new entrants to the existing market is very high, owing to the growing demand for enhanced therapeutics, despite the high entry barriers set by strict regulatory frameworks and capital intensive research and development. The global hospital acquired infection treatment market was valued at US$28.99 bn at the end of 2015 and is expected to expand at a CAGR of 2.7% within a forecast period from 2016 to 2024. By the end of 2024, this market is expected to reach an estimated US$36.61 bn.


Growing Geriatric Population Propels Nosocomial Treatment Demand in Developed Economies

“There is a multi-tracked set of drivers that are currently augmenting the global hospital acquired infection treatment market. Each driver is directly or indirectly linked to the other. Of the many factors in favor of the market’s growth, the leading factor has to be the growing geriatric population. The elderly – due to their lower physical immunity – are incredibly prone to infections and especially nosocomial ones. Therefore, the growing population of the geriatric is a serious factor that needs to be accounted for within the global hospital acquired infection treatment market,” states a TMR analyst.

Other factors driving the global hospital acquired infection treatment market include the overall condition of healthcare organizations in emerging economies. Their generally lower levels of hygiene, infrastructure maintenance and sterilization techniques are creating a very high demand for nosocomial infection treatments. Countries from Asia Pacific, for instance, are currently showing to be leading in terms of growth rate of demand, thereby attracting several prominent players in the global hospital acquired infection treatment market.

Multi-drug Resistant Bacteria Complicating Market Scenario in Nosocomial Infections Treatments

A key restraint acting on the global hospital acquired infection treatment market currently, is the steady increase in the rate of failures in treatment caused by the growing number of multi-drug resistant bacteria. Given a frequent rate of survival of bacteria after being exposed to drugs that are designed to eliminate them, they are known to develop resistance to them, pressuring the healthcare industry to seek alternative treatments or other forms of drug treatments. There is a growing rate of multi-drug resistant bacteria affecting patients and these infections can prove to be heavily detrimental to a patient’s recovery cycle or even be fatal for them.

“Key players in the global hospital acquired infection treatment market are more likely to have multiple drugs in the pipeline, the approval of which can be a shot in the arm for the market. The focus on HAIs is increasing at a fast rate in emerging economies as well, giving rise to a massive untapped market for patients from the lower and middle income classes. These avenues can prove to be fruitful for players currently established in the global hospital acquired infection treatment market, as well as new entrants in emerging economies,” adds the analyst.

The information presented in this review is based on a Transparency Market Research report, titled, “Hospital Acquired Infection Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024.”

Wednesday 7 December 2016

Worldwide Ostomy Drainage Bags Market will reach US$2759.5 Million by 2022

Characterized by the intense rivalry between Coloplast A/S, ConvaTec Inc., and Hollister Inc., the global ostomy drainage bags market demonstrates a highly competitive and consolidated structure. These three players accounted for nearly 85% of the overall market in 2013.

Hitherto, product innovation was the key strategy applied by these players to sustain in this market. However, a shift in their focus towards partnerships, mergers, and acquisitions, in a bid to expand their product portfolio, distribution network, and geographical presence, can be observed in the forthcoming years, reports the study.

Download Complete Healthcare Analytical Brochure: 
http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=325

According to this report, the opportunity in the global market for ostomy drainage bags is likely to increase from a value of US$1.8 bn in 2013 to US$2.7 bn by 2022, expanding at a CAGR of 4.70% during the period from 2014 to 2022. Colostomy bags have been the most valued product in this market and is anticipated to remain so over the period of forecast. Researchers expect the shipment volume of colostomy bags to cross 549.6 million units by the end of 2024.

Europe to Remain Leading Consumer of Ostomy Drainage Bags

A geographical analysis of the global market for ostomy drainage bags is also provided in this research report, according to which, North America, Europe, Asia Pacific, Latin America, the Middle East and North Africa, and the Rest of the World are key regional ostomy drainage bags markets across the world. With the high prevalence of bladder and colorectal cancer, Europe has emerged as the leading consumer of ostomy drainage bags. Holding a near majority share, this regional market will remain dominant throughout the period of forecast.

The presence of a favorable reimbursement scenario, high disposable income of consumers, and the increased awareness among them regarding the available treatment options are likely to fuel the demand for ostomy drainage bags significantly in this region over the next few years. Asia Pacific is also expected to witness a strong rise in the demand for these bags at a CAGR of 5.30% during the forecast period, states the report.

Increasing Geriatric Population Base to Reflect Positively on Sales of Ostomy Drainage Bags

With elderly people being the key consumers of ostomy drainage bags, the ever-increasing geriatric population base has become the main factor behind the growth of the global ostomy drainage bags. “Aging exposes people to a number of health risks, such as colon cancer, bowel cancer, bowel dysfunctions, and incontinence disorders, which necessitate ostomy procedures and the usage of ostomy drainage bags,” says an analyst at TMR.

In addition to this, the increasing incidence of bladder cancer, colorectal cancer, ulcerative colitis, Crohn’s disease, and IBD across the world is anticipated to boost this market considerably over the forecast period. However, the easy availability of alternative ostomy procedures may limit the demand for ostomy drainage bags to some extent in the coming years, notes the market study.

Browse Research Report on Global Ostomy Drainage Bags Market:
http://www.transparencymarketresearch.com/ostomy-drainage-bags-market.html

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR Syndicated Research report covers a different sector - such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.

Contact

Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Browse market research blog:
https://tmrresearch.blogspot.com/